Top Five Innovations to Watch in the Coming Decade

The next decade will see the realization of many of the buzzwords of the last decade. The combination of the information era, the biotechnology revolution, and materials breakthroughs will drive new medical and cleantech inventions that will change our lives. The future of innovation in the United States is promising at its core and we will win unless policy makers accidentally harm innovation. They seem to be trying to do just that, in spite of their rhetoric, by doubling capital gains taxes on investors who fund job-creating cleantech and medical breakthroughs, proposing revised patent laws to penalize innovations, and accidentally constraining capital markets for high-tech with onerous regulations.

Still, here are the five innovations to watch in the coming decade:

1. The Return of Nanotechnology. Although much maligned as a “bubble,” this fundamental set of materials technologies that can unlock new physical properties and combinations of materials has been percolating away. Look for major innovations in solar energy that can produce electricity at 6 cents per kilowatt hour and which will compete with conventional power without subsidy. These are in the field now and will blow away the current big names in solar thermal, concentrated photovoltaics (CPV) and thin film solar. New battery innovations on flexible substrates and new form factors that are 2-5 times more efficient than current lithium ion batteries will emerge from the laboratory.

2. Industrial Applications of Synthetic Biology. Many people think the word “synthetic biology” is a marketing word for “biology.” That is mostly true, but the technical strides in sequencing and synthesis of genes into complex systems is nothing short of mind-boggling. The folks who will succeed here are not the providers of the biology, but those who understand and own the biology AND can integrate it into industries like fuel, and agriculture. Companies like Sapphire Energy are already developing technologies that will revolutionize fuels and agriculture as we know it. The United States will produce our own green crude oil at home and at huge scale by 2020.

3. P4 Medicine. A term coined by Leroy Hood to embody Personalized, Predictive, Preventive, and Participatory medicine. This technology will come of age. Driven by new cost reductions in the ability to sequence human genomes, we will finally be able to understand who will get disease, detect the disease early, and administer medicines that will work, only to those who need it. Medicine will be more cost effective and more targeted and “Smart pills” will be better and cheaper than expensive hospitals. The biggest barriers here are political—none of this will happen without

Author: Robert Nelsen

Robert Nelsen is a co-founder and a Managing Director of ARCH Venture Partners. He focuses on biotechnology, pharmaceuticals, and nanotechnology. Mr. Nelsen joined ARCH at its founding and has played a significant role in the early sourcing, financing and development of more than thirty companies including Ikaria, Adolor (ADLR), Aviron (AVIR, acquired by Medimmune-MEDI), Caliper Life Sciences (CALP), Illumina (ILMN), Trubion Pharmaceuticals (TRBN), Array BioPharma (ARRY), NetBot, deCODE Genetics (DCGN), Nanosys, Alnylam Pharmaceuticals (ALNY), XenoPort (XNPT), GenVec (GNVC), R2 Technology (acquired by Hologic-HOLX), IDUN Pharmaceuticals (acquired by Pfizer-PFE), Genomica (GNOM, acquired by Exelixis-EXEL), Surface Logix, NeurogesX (NGSX), Classmates.com (acquired by United Online-UNTD), Nura (acquired by Omeros), Kythera Biopharmaceuticals, Elixir Pharmaceuticals, Spaltudaq, VLST, Ensemble Discovery, Accelerator, Apoptos, Fate Therapeutics, Agios Therapeutics, and Everyday Learning. Mr. Nelsen is a director of Sapphire Energy, Ikaria, Agios, NeurogesX, and Kythera Biopharmaceuticals. He previously served on the boards of Trubion Pharmaceuticals, Surface Logix, NetBot, Everyday Learning, Spaltudaq, Array BioPharma, Caliper Life Sciences, Illumina, R2 Technology, and Classmates.com, among others. He also serves as a director of the Fred Hutchinson Cancer Research Center. Mr. Nelsen holds an M.B.A. from The University of Chicago and a B.S. in Economics and Biology from the University of Puget Sound.